Clinical trial · Observational
ImmuNe ParameTERs to Predict Immunotherapy REsponse and Toxicity (INTERPRET)
NCT06900296CI-TRIAL-00118055INTERPRETnot yet recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a prospective observational study that will collect blood samples at 1-10 timepoints related to initiation of immunotherapy. The study may collect samples before the start of immunotherapy and/or at clinically significant timepoints during immunotherapy treatment.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Quantification of plasma concentrations
- timeFrame
- through study completion (i.e. up to 12 months)
- description
- Including cytokines, chemokines, growth factors, and other relevant immunologic molecules from blood samples
- measure
- Profiling of immune cells
- timeFrame
- through study completion (i.e. up to 12 months)
- description
- Plasma concentrations of immunologic molecules will be assayed using immunoassays or plasma proteomic approaches. Profiling of immune cells will be performed using flow cytometry, RNA sequencing, and other established approaches.
Secondary outcomes (1)
- measure
- Assessment of genomic variants
- timeFrame
- through study completion (i.e. up to 12 months)
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. ≥ 18 years old at the time of informed consent. 2. Have a diagnosis of cancer and initiating therapy with single agent or combination therapy that includes an immunotherapy (see Appendix 16.1 for list of immunotherapy classes). 3. Ability to provide written informed consent and HIPAA authorization. Exclusion Criteria: 1\. Not meeting any of the previously described inclusion criteria.
References
Publications (0)
Data not yet available
No reference posted for this study.